Lee J - Search Results

1

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.

Lee J, Kida K, Koh J, Liu H, Manyam GC, Gi YJ, Rampa DR, Multani AS, Wang J, Jayachandran G, Lee DW, Reuben JM, Sahin A, Huo L, Tripathy D, Im SA, Ueno NT. Lee J, et al. Among authors: lee dw. J Exp Clin Cancer Res. 2024 Aug 21;43(1):236. doi: 10.1186/s13046-024-03143-3. J Exp Clin Cancer Res. 2024. PMID: 39164784 Free PMC article.

2

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.

Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. Lee J, et al. Breast Cancer Res Treat. 2014 Jul;146(2):259-72. doi: 10.1007/s10549-014-3014-7. Epub 2014 Jun 12. Breast Cancer Res Treat. 2014. PMID: 24916181 Free PMC article.

3

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.

Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. Sohn J, et al. Among authors: lee j. J Cancer. 2014 Oct 15;5(9):745-53. doi: 10.7150/jca.9696. eCollection 2014. J Cancer. 2014. PMID: 25368674 Free PMC article.

4

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT. Torres-Adorno AM, et al. Among authors: lee j. Clin Cancer Res. 2017 Aug 15;23(16):4780-4792. doi: 10.1158/1078-0432.CCR-16-2622. Epub 2017 May 2. Clin Cancer Res. 2017. PMID: 28465444 Free PMC article.

5

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Lee J, et al. Breast Cancer Res Treat. 2019 Jun;175(2):339-351. doi: 10.1007/s10549-019-05166-3. Epub 2019 Mar 2. Breast Cancer Res Treat. 2019. PMID: 30826934 Free PMC article.

6

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. Lim B, et al. Among authors: lee j. Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17. Br J Cancer. 2019. PMID: 31097774 Free PMC article. Clinical Trial.

7

Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.

Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NT. Xie X, et al. Among authors: lee j. Mol Cancer Ther. 2021 Feb;20(2):296-306. doi: 10.1158/1535-7163.MCT-19-1160. Epub 2020 Dec 15. Mol Cancer Ther. 2021. PMID: 33323457 Free PMC article.

8

Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.

Yamaguchi A, Anami Y, Ha SYY, Roeder TJ, Xiong W, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Yamaguchi A, et al. Among authors: lee j. Bioorg Med Chem. 2021 Feb 15;32:116013. doi: 10.1016/j.bmc.2021.116013. Epub 2021 Jan 9. Bioorg Med Chem. 2021. PMID: 33482584

9

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.

Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Yamazaki CM, et al. Among authors: lee j. Nat Commun. 2021 Jun 10;12(1):3528. doi: 10.1038/s41467-021-23793-7. Nat Commun. 2021. PMID: 34112795 Free PMC article.

10

Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.

Xie X, Lee J, Iwase T, Kai M, Ueno NT. Xie X, et al. Among authors: lee j. Expert Opin Ther Targets. 2022 May;26(5):405-425. doi: 10.1080/14728222.2022.2077188. Epub 2022 May 23. Expert Opin Ther Targets. 2022. PMID: 35574694 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146,707 results

Search Page

Filters